Fas associated factor family member 2Genealiases: ETEA · UBXD8 · UBXN3B
Q-omics provides the consensus-scored FAF2 profile across patient tissues and cancer cell-line models. FAF2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAF2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, FAF2 protein abundance shows 26,230 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, KIRC, and LUAD as cancer lineages where FAF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAF2 survival associations across molecular data types. FAF2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAF2 RNA expression–survival associations across cancer types. High FAF2 expression shows unfavorable associations in UVM, KIRP, KICH, HNSC and LIHC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FAF2 RNA expression.
This table summarizes FAF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAF2 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, LIHC, KIRP and LUAD. The KIRC box plot shows higher FAF2 RNA expression in tumor versus normal tissue (log2 FC = +0.954, t-test p < 0.001).
This table shows molecular features associated with FAF2 in patient tissues and cancer cell lines. In patient samples, FAF2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FAF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
